XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Net sales $ 585.4 $ 610.8
Cost of goods sold 279.4 284.9
Gross profit 306.0 325.9
Selling, general and administrative expense 208.8 214.9
Research and Development Expense 73.5 66.4
Segment profit (loss) 23.7 44.6
Interest expense 12.0 12.3
Foreign exchange (gains) losses, net (2.7) (2.0)
Marketable Securities, Unrealized (Gain) Loss (31.8) (422.2)
Other Nonoperating Income (Expense) 37.2 34.6
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 83.4 491.1
(Provision) benefit for income taxes (19.4) (107.2)
Net income attributable to Bio-Rad $ 64.0 $ 383.9
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ 2.29 $ 13.46
Weighted average common shares - basic 27,941 28,518
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ 2.29 $ 13.45
Weighted average common shares - diluted 27,955 28,537